AUA 2020: Clinical Utility of Preoperative PSMA-targeted 18F-DCFPyL PET/CT in Men with High-risk Prostate Cancer: Diagnostic Performance Comparisons with Pelvic CT or MRI in the OSPREY Prospective, Multi-center Trial

(UroToday.com) There is no molecular imaging agent approved for the initial staging of prostate cancer. Current imaging modalities are suboptimal for the initial staging of men at risk of harboring occult metastatic prostate cancer because of the low positive and negative predictive values of pelvic CT/MRI for detecting regional nodal metastases.¹ Because ¹⁸F-FDG positron emission tomography (PET) /computerized tomography (CT) is not accurate to stage or re-stage prostate cancer, a number of metabolisms associated PET tracers have been developed to improve PET/CT accuracies, such as fluoro-choline and fluciclovine.